Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis
Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis
复制标题
DOI：
10.2169/internalmedicine.3098-19
复制
发表时间：
2020-01-01
影响因子：
1.2
通讯作者：
Hara, Tetsuya
中科院分区：
文献类型：
--
作者：
Ishii, Koji;Yamashita, Haruna;Hara, Tetsuya
阿片诱导性便秘(OIC)可通过一种新的机制被纳地丁和其他外周作用的Mu-阿片受体拮抗剂(PAMORA)所治疗。我们描述了一个52岁的女性门诊病人，她在接受羟考酮治疗癌症多发性骨转移引起的疼痛时发生了OIC。虽然她没有脑转移，但口服纳尔德定后出现了阿片戒断综合征(OWS)。她的临床阿片戒断评分(奶牛)为19(中度症状)。然而，她在静脉注射芬太尼和持续输注羟考酮的情况下从OWS中恢复过来。此后，她没有发展为OWS，康复两天后出院。
Opioid-induced-constipation (OIC) can be treated by naldemedine and other peripherally acting mu-opioid receptor antagonists (PAMORA) via a novel mechanism. We describe the case of a 52-year-old female outpatient who developed OIC while receiving oxycodone for pain due to cancer with multiple bone metastases. Although she did not have brain metastasis, opioid withdrawal syndrome (OWS) developed after taking naldemedine orally. Her Clinical Opiate-Withdrawal Score (COWS) was 19 (moderate symptoms). However, she recovered from OWS on intravenous fentanyl and a continuous infusion of oxycodone. She did not develop OWS thereafter and was discharged two days after recovery.